Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Fujifilm to buy Atara cell therapy plant

by Michael McCoy
February 4, 2022 | A version of this story appeared in Volume 100, Issue 5

Fujifilm has agreed to acquire a cell therapy production facility from Atara Biotherapeutics for $100 million. The facility, in Thousand Oaks, California, can make allogeneic T-cell and CAR T-cell immunotherapies. Fujifilm says the purchase expands its biologic drug contract manufacturing services to the US West Coast, complementing facilities in Massachusetts, Texas, and England. Fujifilm will manufacture therapies in Atara’s pipeline under a long-term agreement.

Article:

This article has been sent to the following recipient:

1 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.